WHO ICTRP trial
REPRIEVE STUDY (A5332 PROTOCOL)
PER-012-17 · Registro Peruano de Ensayos Clínicos (REPEC) · Recruiting
Key facts
| Trial ID | PER-012-17 |
|---|---|
| Public title | REPRIEVE STUDY (A5332 PROTOCOL) |
| Scientific title | RANDOMIZED TRIAL TO PREVENT VASCULAR EVENTS IN HIV |
| Primary sponsor | Institutos Nacionales de Salud (NIH, siglas en ingles) de los Estados Unidos de America, |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | IV |
| Countries | Haiti;Peru;United States;Puerto Rico;Zimbabwe;Brazil;Canada |
| Conditions | -B24 Unspecified human immunodeficiency virus [HIV] disease Unspecified human immunodeficiency virus [HIV] disease;B24 |
| Interventions | ARM A: Pitavastatin 4 mg one tablet once daily taken orally with or without food, until 72 months. ARM B: Placebo for pitavastatin one tablet once daily taken orally with or without food, until 72 months. |
| Registration date | Jul 18, 2017 |
| Target size | 400 |
| Secondary IDs | NCT02344290 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: